Smoothened Inhibition Leads to Decreased Proliferation and Induces Apoptosis in Esophageal Adenocarcinoma Cells

REFERENCES

• Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5(12):1026–1033.
   PubMed Web of Science ®Google Scholar
• Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15(23): 3059–3087.
   PubMed Web of Science ®Google Scholar
• Lin TL, Matsui W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. OncoTargets and Ther 2012;5:47–58.
   PubMed Web of Science ®Google Scholar
• Marini KD, Payne BJ, Watkins DN, Martelotto LG. Mechanisms of Hedgehog signalling in cancer. Growth Factors 2011;29(6):221–234.
   PubMed Web of Science ®Google Scholar
• Shahi MH, Afzal M, Sinha S, Eberhart CG, Rey JA, Fan X, Castresana JS. Regulation of sonic hedgehog-GLI1 downstream target genes PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKX2.2 and their epigenetic status in medulloblastoma and astrocytoma. BMC Cancer 2010;10:614–633.
   PubMedGoogle Scholar
• Watkins DN, Berman DM, Baylin SB. Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle 2003;2(3):196–198.
   PubMedGoogle Scholar
• Sui G, Bonde P, Dhara S, Broor A, Wang J, Marti G, Feldmann G, Duncan M, Montgomery E, Maitra A, Harmon JW. Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model. J Surg Res 2006;134(1):1–9.
   PubMed Web of Science ®Google Scholar
• Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res 2011;71(3):1092–1102.
   PubMed Web of Science ®Google Scholar
• Chen X, Horiuchi A, Kikuchi N, Osada R, Yoshida J, Shiozawa T, Konishi I. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci 2007;98(1):68–76.
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkin DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297(5586):1559–1561.
   PubMed Web of Science ®Google Scholar
• Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PloS One 2010;5(12):e15262.
   PubMedGoogle Scholar
• Merchant AA, Matsui W. Targeting Hedgehog—a cancer stem cell pathway. Clin Cancer Res 2010;16(12):3130–3140.
   PubMed Web of Science ®Google Scholar
• Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007;17(2):165–172.
   PubMed Web of Science ®Google Scholar
• Ruiz i Altaba A. Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets. Cancer Cell 2008;14(4):281–213.
   PubMed Web of Science ®Google Scholar
• Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 2009;1(6–7):338–351.
   PubMed Web of Science ®Google Scholar
• Dodge ME, Lum L. Drugging the cancer stem cell compartment: lessons learned from the hedgehog and Wnt signal transduction pathways. Annu Rev Pharmacol Toxicol 2011;51:289–310.
   PubMed Web of Science ®Google Scholar
• Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PloS One 2011;6(11):e27306.
   PubMed Web of Science ®Google Scholar
• Rodova M, Fu J, Watkins DN, Srivastava RK, Shankar S. Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PloS One 2012;7(9):e46083.
   PubMed Web of Science ®Google Scholar
• Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer 2012;131(1):30–40.
   PubMed Web of Science ®Google Scholar
• Coni S, Infante P, Gulino A. Control of stem cells and cancer stem cells by Hedgehog signaling: Pharmacologic clues from pathway dissection. Biochem Pharmacol 2013;85(5):623–628.
   PubMed Web of Science ®Google Scholar
• Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg 2011;30(4 Suppl):S14–S18.
   PubMed Web of Science ®Google Scholar
• Bristol Meyers Squibb. Phase 1b multiple ascending dose study of BMS-833923 (XL139) administered in combination with cisplatin and capecitabine as first-line therapy in patients with inoperable metastatic gastric, gastroesophageal, or esophageal adenocarcinomas 2009. www.clinicaltrials.gov/show/NCT00909402.
   Google Scholar
• LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Bored MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17(8):2502–2511.
   PubMed Web of Science ®Google Scholar
• Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, LoRusso PM. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011;17(8):2512–2520.
   PubMed Web of Science ®Google Scholar
• Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366(23):2180–2188.
   PubMed Web of Science ®Google Scholar
• Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009;30(6):303–312.
   PubMed Web of Science ®Google Scholar
• Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004;431(7009):707–712.
   Google Scholar
• Mazumdar T, Devecchio J, Agyeman A, Shi T, Houghton JA. Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res 2011;71(17):5904–5914.
   PubMed Web of Science ®Google Scholar
• Wang DH, Clemons NJ, Miyashita T, Dupuy AJ, Zhang W, Szczepny A, Corcoran-Schwartz IM, Wilburn DL, Montgomery EA, Wang JS, Jenkins NA, Copeland NA, Harmon JW, Phillips WA, Watkins DN. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 2010;71(17):5904–5914.
   Google Scholar
• Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, Kosovec JE, Bhatt A, Malhotra U, Foxwell T, Rotoloni CL, Hoppo T, Jobe BA. Prevention of Barrett's esophagus and esophageal adnocarcinoma by smoothend inhibitor in a rat model of gastroesophageal reflux disease. Ann Surg 2013;258(1):82–88.
   PubMed Web of Science ®Google Scholar
• Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62(2):118–128.
   PubMed Web of Science ®Google Scholar
• Yoon HH, Gibson MK. Combined-modality therapy for esophageal and gastroesophageal junction cancers. Curr Oncol Rep 2007;9(3):184–192.
   PubMedGoogle Scholar
• Yang L, Wang LS, Chen XL, Gatalica Z, Qiu S, Liu Z, Stoner G, Zhang H, Weiss H, Xie J. Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. Int J Biochem Mol Biol 2012;3(1):46–57.
   PubMedGoogle Scholar
• Underwood TJ, Derouet MF, White MJ, Noble F, Moutasim KA, Smith E, Drew PA, Thomas GJ, Primrose JN, Blaydes JP. A comparison of primary oesophageal squamous epithelial cells with HET-1A in organotypic culture. Biol Cell 2010;102(12):635–644.
   PubMed Web of Science ®Google Scholar
• Pogoriler J, Millen K, Utset M, Du W. Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation. Development 2006;133(19):3929–3937.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Sutherlin D, Scales SJ, Gould SE, Yauch RL, de Sauvage FJ. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011;71(2):435–444.
   PubMed Web of Science ®Google Scholar
• Mazumdar T, DeVecchio J, Agyeman A, Shi T, Houghton JA. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget 2011;2(8):638–645.
   PubMedGoogle Scholar
• Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326(5952):572–574.
   PubMed Web of Science ®Google Scholar
• Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011;71(15):5057–5061.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Demars CJ, Comba A, Gainullin VG, Rizvi Z, Almada LL, Wang K, Lomberk G, Fernandez-Zapico ME, Buttar NS. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res 2010;70(17):6787–6796.
   PubMed Web of Science ®Google Scholar